Nath, Karthik
Shekarkhand, Tala
Nemirovsky, David
Derkach, Andriy http://orcid.org/0000-0003-2178-8493
Costa, Bruno Almeida http://orcid.org/0000-0002-1816-4498
Nishimura, Noriko
Farzana, Tasmin
Rueda, Colin
Chung, David J. http://orcid.org/0000-0003-0469-839X
Landau, Heather J. http://orcid.org/0000-0002-3152-1189
Lahoud, Oscar B. http://orcid.org/0000-0002-3291-286X
Scordo, Michael
Shah, Gunjan L. http://orcid.org/0000-0002-9977-0456
Hassoun, Hani http://orcid.org/0000-0002-2036-1749
Maclachlan, Kylee http://orcid.org/0000-0001-7873-4854
Korde, Neha http://orcid.org/0000-0002-5538-4318
Shah, Urvi A. http://orcid.org/0000-0001-8419-1091
Tan, Carlyn Rose http://orcid.org/0000-0001-7922-2594
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Giralt, Sergio A. http://orcid.org/0000-0003-1944-5053
Usmani, Saad Z. http://orcid.org/0000-0002-5484-8731
Shahid, Zainab
Mailankody, Sham http://orcid.org/0000-0002-2815-9561
Lesokhin, Alexander M. http://orcid.org/0000-0001-9321-702X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 30 January 2024
Revised: 20 March 2024
Accepted: 22 March 2024
First Online: 31 May 2024
Competing interests
: TS reports honoraria from Genentech; DJC receives research funding from Genentech; HJL has served as a paid consultant for Takeda, Genzyme, Janssen, Karyopharm, Pfizer, Celgene, Caelum Biosciences, and has received research support from Takeda; OBL reports serving on Advisory Board for MorphoSys Inc., Kite, Daiichi Sankyo Inc., Incyte; Consulting for: Incyte; MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, and Amgen, Inc.; served on ad hoc advisory boards for Kite – A Gilead Company; and received honoraria from i3Health, Medscape, and CancerNetwork for CME-related activity; GS reports research funding from Janssen, Amgen, BMS, Beyond Spring, and serves on the Data Safety Monitoring Board for ArcellX. GS research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR, and on DSMB for ArcellX; HH reports grants from Celgene, Takeda, and Janssen, outside the submitted work; NK reports research funding through Amgen and participates in advisory board with Medimmune; US reports personal fees from Physicians Educations Resources; grants and other from Celgene/Bristol Myers Squibb; other from Janssen; and grants from Parker Institute for Cancer Immunotherapy and Myeloma Crowd, outside the submitted work; CT: reports research funding from Janssen and personal fees from Physician Educations Resource; MH: reports research funding from Amgen, Daiichi Sankyo, GlaxoSmithKline; has received honoraria for consultancy/participated in advisory boards for Curio Science LLC, Intellisphere LLC, Bristol Myer Squibb, and GlaxoSmithKline; SAG reports personal fees from and an advisory role (scientific advisory board) in Actinium, Celgene, Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite, outside the submitted work; SZU reports grants and personal fees from AbbVie, 404 Amgen, BMS, Celgene, GSK, Janssen, Merck, MundiPharma, Oncopeptides, 405 Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; SM received consulting fees from Evicore, Optum, BioAscend, Janssen Oncology, Bristol Myers Squibb, AbbVie, ECor1, Galapagos, and Legend Biotech. Memorial Sloan Kettering Cancer Center receives research funding from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics, and Takeda Oncology for research led by Sham Mailankody. Sham Mailankody received honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications; AML reports grants from Bristol Myers Squibb; personal fees from Trillium Therapeutics; grants, personal fees and non-financial support from Pfizer; and grants and personal fees from Janssen and Arcellx, outside the submitted work. AML also has a patent US20150037346A1 with royalties paid.